Saturna Capital CORP raised its stake in shares of Celgene Co. (NASDAQ:CELG) by 1.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 211,984 shares of the biopharmaceutical company’s stock after purchasing an additional 2,125 shares during the period. Saturna Capital CORP’s holdings in Celgene were worth $22,123,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Capital Counsel LLC NY lifted its holdings in Celgene by 0.4% during the second quarter. Capital Counsel LLC NY now owns 1,649 shares of the biopharmaceutical company’s stock valued at $214,000 after purchasing an additional 6 shares in the last quarter. Fort Pitt Capital Group LLC lifted its holdings in Celgene by 0.6% during the second quarter. Fort Pitt Capital Group LLC now owns 1,925 shares of the biopharmaceutical company’s stock valued at $250,000 after purchasing an additional 11 shares in the last quarter. TCI Wealth Advisors Inc. raised its position in shares of Celgene by 0.9% in the second quarter. TCI Wealth Advisors Inc. now owns 3,043 shares of the biopharmaceutical company’s stock valued at $395,000 after buying an additional 26 shares during the last quarter. Linscomb & Williams Inc. raised its position in shares of Celgene by 1.0% in the second quarter. Linscomb & Williams Inc. now owns 3,813 shares of the biopharmaceutical company’s stock valued at $495,000 after buying an additional 36 shares during the last quarter. Finally, Courier Capital LLC raised its position in shares of Celgene by 1.9% in the second quarter. Courier Capital LLC now owns 1,987 shares of the biopharmaceutical company’s stock valued at $258,000 after buying an additional 38 shares during the last quarter. 78.67% of the stock is currently owned by institutional investors and hedge funds.
Shares of Celgene Co. (CELG) opened at $91.56 on Wednesday. Celgene Co. has a 12-month low of $86.55 and a 12-month high of $147.17. The firm has a market cap of $69,410.77, a PE ratio of 13.45, a price-to-earnings-growth ratio of 0.65 and a beta of 1.58. The company has a debt-to-equity ratio of 2.29, a quick ratio of 4.80 and a current ratio of 4.99.
Celgene declared that its board has approved a stock buyback plan on Wednesday, February 14th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the biopharmaceutical company to buy shares of its stock through open market purchases. Shares repurchase plans are usually an indication that the company’s board believes its stock is undervalued.
In other Celgene news, Director Ernest Mario sold 13,370 shares of Celgene stock in a transaction dated Friday, February 23rd. The shares were sold at an average price of $94.49, for a total transaction of $1,263,331.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director Gilla Kaplan sold 9,250 shares of the firm’s stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $95.99, for a total transaction of $887,907.50. Following the completion of the transaction, the director now directly owns 94,801 shares of the company’s stock, valued at approximately $9,099,947.99. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 41,120 shares of company stock valued at $3,879,509. Company insiders own 0.95% of the company’s stock.
A number of equities research analysts have recently commented on the stock. Cantor Fitzgerald set a $112.00 target price on shares of Celgene and gave the company a “hold” rating in a research report on Tuesday, January 23rd. Deutsche Bank assumed coverage on shares of Celgene in a research report on Tuesday, December 12th. They issued a “hold” rating and a $114.00 target price for the company. Robert W. Baird reiterated a “hold” rating and issued a $92.00 target price on shares of Celgene in a research report on Thursday, March 1st. TheStreet cut shares of Celgene from a “b-” rating to a “c+” rating in a research report on Friday, November 17th. Finally, SunTrust Banks set a $127.00 target price on shares of Celgene and gave the company a “buy” rating in a research report on Monday, January 8th. Two equities research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, seventeen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. Celgene has an average rating of “Buy” and an average price target of $128.22.
TRADEMARK VIOLATION WARNING: “Celgene Co. (CELG) Holdings Boosted by Saturna Capital CORP” was originally reported by American Banking News and is owned by of American Banking News. If you are viewing this article on another publication, it was stolen and republished in violation of US and international trademark and copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2018/03/14/celgene-co-celg-holdings-boosted-by-saturna-capital-corp.html.
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.